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PEP005 is a novel ingenol angelate that modulates protein kinases C (PKC) functions by activating PKCd and inhibiting PKCa. This
study assessed the antiproliferative effects of PEP005 alone and in combination with several other anticancer agents in a panel of 10
human cancer cell lines characterised for expression of several PKC isoforms. PEP005 displayed antiproliferative effects at clinically
relevant concentrations with a unique cytotoxicity profile that differs from that of most other investigated cytotoxic agents, including
staurosporine. In a subset of colon cancer cells, the IC50 of PEP005 ranged from 0.01–140mM. The antiproliferative effects of PEP005
were shown to be concentration- and time-dependent. In Colo205 cells, apoptosis induction was observed at concentrations ranging
from 0.03 to 3mM. Exposure to PEP005 also induced accumulation of cells in the G1 phase of the cell cycle. In addition, PEP005
increased the phosphorylation of PKCd and p38. In Colo205 cells, combinations of PEP005 with several cytotoxic agents including
oxaliplatin, SN38, 5FU, gemcitabine, doxorubicin, vinorelbine, and docetaxel yielded sequence-dependent antiproliferative effects.
Cell cycle blockage induced by PEP005 in late G1 lasted for up to 24h and therefore a 24h lag-time between PEP005 and
subsequent exposure to cytotoxics was required to optimise PEP005 combinations with several anticancer agents. These data
support further evaluation of PEP005 as an anticancer agent and may help to optimise clinical trials with PEP005-based combinations
in patients with solid tumours.
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Protein kinase C (PKC) is a family of serine/threonine kinases
comprising at least 12 isoenzymes that are effectors of diacyl-
glycerol and the main targets of phorbol-ester tumour promoters
(Ghoul et al, 2005). Protein kinases C have been shown to play an
important role in a variety of cellular events, including cellular
proliferation, cell cycle progression, differentiation, drug efflux,
apoptosis, and tumour angiogenesis (Serova et al, 2006). Evidence
has suggested that selective targeting of PKC may enhance the
therapeutic efficacy of established chemotherapeutic agents and
sensitise cancer cells to ionising radiation (Mackay and Twelves,
2007). Various PKC modulators with promising anticancer activity
as single agents have been tested to reverse resistance to cytotoxic
chemotherapy, providing a rationale for the development of drug
combinations with PKC modulators in a number of human
tumours.
The expression of PKC isozymes in tumours has been shown to
be partially tissue specific (Pongracz et al, 1995; Verstovsek et al,
1998; Griner and Kazanietz, 2007). Protein kinase Ca has been
shown to play a role in cellular proliferation and invasion, PKCb
seems to promote invasion (Zhang et al, 2004), the bII isoform
being an important mediator of VEGF-induced angiogenesis
(Teicher et al, 2001; Suzuma et al, 2002), and PKCe was shown
to promote cell survival through the activation of the AKT pathway
and upregulation of several survival factors. In addition, PKCd was
shown to play a key role in cell survival and apoptosis. Protein
kinase Cd may be activated in response to Ara-C as demonstrated
in U937 human leukaemia cells (Emoto et al, 1996), cisplatin in
H69 human small-cell lung cancer cells (Persaud et al, 2005), and
etoposide in human glioma cells (Blass et al, 2002). Interestingly,
apoptosis was severely impaired when the PKCd function or
expression was inhibited (Humphries et al, 2006). In addition,
activation of PKCd may cause G1 and G2 cell cycle arrest through
the modulation of cyclin and cyclin-dependent kinase expression
(Griner and Kazanietz, 2007). Thus, PKCd is regarded as an
attractive target for therapeutic interventions.
PEP005 is a novel ingenol angelate extracted and purified from
Euphorbia peplus. Chemically, PEP005 is structurally analogous to
phorbol esters (Figure 1) and is a potent modulator of PKC
isoenzymes (Kedei et al, 2004). PEP005 is currently being
developed as a topical treatment for actinic keratoses and basal
cell carcinoma (www.cancertrials.gov). In earlier studies, PEP005 Revised 4 August 2008; accepted 6 August 2008
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swas shown to modulate PKCs by activating PKCd in human
myeloid leukaemia cancer cell lines, thereby inducing cellular
apoptosis (Hampson et al, 2005) in melanoma models, inducing
senescence through PKC-mediated activation of the MAPK path-
way (Cozzi et al, 2006) and in colon cancer models, inducing
apoptosis through the inhibition of the AKT signalling pathway
(Serova et al., 2008). PEP005 appears to be selective for growth
inhibition of cancer cells as it does not inhibit the growth of
human neonatal fibroblasts (Cozzi et al, 2006) and does not induce
apoptosis in normal CD34þ cord blood myeloblasts (Hampson
et al, 2005). In leukaemia cells, resistance to PEP005 was associated
with the failure to express PKCd. In solid tumours, PEP005 was
shown to induce necrosis in human melanoma, cervical cancer,
and prostate xenografts (Ogbourne et al, 2004).
The aim of our study was to investigate antiproliferative effects
of PEP005 in a panel of colon cancer cell lines that expressed
various levels of PKCd and to evaluate the effects of PEP005-based
combinations with cytotoxic agents commonly used for the
treatment of cancer.
MATERIALS AND METHODS
Cell lines and reagents
The HT29 colon cancer, MCF7 breast cancer, and OVCAR3 ovarian
cancer cell lines were obtained from the American Type Culture
Collection (Rockville, MD, USA) and maintained according to its
recommendations. Colo205, HCT116, HCC2998 colon, HOP62 and
HOP92 lung, IGROV1 ovarian, and MDA-MB-435 breast cancer
cell lines were obtained from NCI (Bethesda, MD, USA). All cell
lines were regularly tested for mycoplasma contamination by PCR
using a Stratagene kit (Austin, TX, USA).
Purified PEP005 was supplied by Peplin Ltd (Brisbane,
Australia). Cytotoxic agents were prepared in DMSO or other
solvents, as appropriate. Cisplatin (Sigma, St Quentin Fallavier,
France), oxaliplatin (Sanofi-Aventis, Paris, France), doxorubicin
(Teva, Paris, France), gemcitabine (Lilly, Suresnes, France), 5FU
(Teva, France), vinorelbine (Pierre Fabre, Boulogne, France),
docetaxel (Sanofi-Aventis, France), and staurosporine (Sigma,
France) were used.
In vitro growth inhibition assay (MTT assay)
The data generated were from three separate experiments, each
performed in duplicate. Cell viability was determined using the
MTT assay, which was carried out as described previously (Hansen
et al, 1989). Briefly, cells were seeded in 96-well plates at a density
of 2 10
3 cells per well. For single-agent studies, cells were seeded
and allowed to settle for 24h before treatment with increasing
concentrations of PEP005 or cytotoxics. After incubation, the cells
were allowed to recover in compound-free medium for 72h, before
determination of growth inhibition using the MTT assay. Cells
were incubated with 0.4mgml
 1 of MTT dye (3-[4, 5-dimethylthia-
zol-2-yl]-2, 5-diphenyltetrazolium bromide; Sigma, France) for 4h
at 371C. The monolayer was suspended in 0.1ml of DMSO and the
absorbance at 560nm was measured using a microplate reader
(Thermo, Villebon-sur-Yvette, France). The control value corre-
sponding to untreated cells was taken as 100% and the viability of
treated samples was expressed as a percentage of the control. The
IC50 values were determined as the concentration that reduced cell
viability by 50%.
Combination studies
For simultaneous drug exposure, cells were seeded at 2 10
3 cells
per well in 96-well plates and treated 24h later with increasing
concentrations of PEP005 alone or with concentrations of cytotoxic
agents corresponding to the IC20,I C 40,I C 60,o rI C 80 values. Drugs
were either added simultaneously for 24h or given using sequential
exposures. For sequential exposures, cells were incubated with
different concentrations of PEP005 for 24h before or following
treatment with other drugs. The cells were washed twice in drug-
free medium then post-incubated in drug-free medium for 72h.
Growth inhibition was then determined by the MTT assay. A
washout period of 24h between exposures to the two drugs,
followed by 48h in drug-free culture medium was also studied.
Statistical analysis and determination of synergistic
activity
Drug combination effects were determined using the Chou and
Talalay method as described elsewhere (Chou and Talalay, 1984)
based on the median effect principle. The combination index (CI)
values of o1 indicate synergy, a value of 1 indicates additive
effects, and a value of 41 indicates antagonism. Variability
between experiments led us to consider that CI values ranging
from 0.8 to 1.2 represent additive effects. Thus a CI below 0.8
indicates synergy, above 1.2 antagonism, and between 0.8 and 1.2
additive effects. Data were analysed using concentration effect
analysis software (Biosoft, Cambridge, UK). For statistical analysis
and graphs, Prism software (GraphPad, CA, USA) was used.
Experiments were performed three times, in duplicate. Means
and standard deviations were compared using Student’s t-test
(two-sided P-value).
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Figure 1 Chemical structure of PEP005 and phorbol 12-myristate 13-acetate (PMA).
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Cell cycle analysis were studied by flow cytometry. In brief, cells
were seeded in 25cm
3 flasks and treated with various concentra-
tions of PEP005 or cytotoxics. At various time points, adherent and
non-adherent cells were recovered, washed twice in PBS, fixed in
70% ethanol, and stored at 41C until analysed. Cells were washed
twice in PBS, incubated for 20min at room temperature with
250mgml
 1 RNAse A and 20min at 41C with 50mgml
 1 propidium
iodide (PI). The cell cycle distribution and percentage of apoptotic
cells were determined using a FACScan flow cytometer (Becton
Dickinson, Le-Pont-de-Claix, NJ, USA).
Apoptosis
The measurement of the percentage of apoptotic cells was assessed
by flow cytometry using double staining annexin V-FITC and PI.
The Annexin V kit (Sigma, France) was used. Cells were prepared
according to the manufacturer’s protocol. Cell distribution was
determined using a FACScan flow cytometer (Becton Dickinson).
Western blot analysis
Cells were lysed in buffer containing 50mM HEPES (pH 7.6),
150mM NaCl, 1% Triton X-100, 2mM vanadate, 100mM NaF, and
0.40mgml
 1 phenylmethyl fluoride. Equal amounts of protein
(20mg per lane) were subjected to SDS–PAGE and transferred to
nitrocellulose membranes. Membranes were blocked with 5% milk
in 0.05% Tween-20/TBS and then incubated with the first antibody
overnight. Membranes were then incubated with the secondary
anti-mouse or anti-rabbit horseradish peroxidase conjugated
antibody. Bands were visualised using the enhanced chemilumi-
nescence Western blotting detection system (ECL, Amersham, NJ,
USA). Densitometric analysis was performed under conditions that
yielded a linear response. The following antibodies were used: anti-
PKCs a, b, d, and e (Cell Signalling, Saint Quentin Yvelines,
France), anti-phospho-PKC d (Upstate Biotechnology, Hampshire,
UK), and anti-phospho-p38 (BD Biosciences, Le-Pont-de-Claix,
France).
RESULTS
Antiproliferative effects of PEP005 in cancer cell lines with
various PKC expressions
We first evaluated the expression of PKC isoforms a, b, d, and e in
a panel of 10 human cancer cell lines representing common human
cancers (breast, lung, colon, and ovarian cancer). The mRNA and
protein expression levels of PKCs were assessed by RT–PCR (data
not shown) and western blot analysis. Protein kinase C isoforms
a and d, which are targets of PEP005, were expressed at various
levels in the panel of cell lines. On the basis of these results, we
selected four colon cancer cell lines for further experiments. Those
cells were considered as representative as they displayed different
levels of PKCa and PKCd expression. The antiproliferative effects
were assessed by MTT assay for durations of exposure varying
between 1 and 48h (Table 1). In our panel of colon cancer cells,
exposure to PEP005 for 48h led to higher antiproliferative effects
than shorter exposure times (Table 1 and Figure 2A). Colo205,
HCC2998, HCT116, and HT29 cells displayed IC50 values of 0.01,
30.0, 120.0, and 140.0mM after 48h PEP005 exposure, respectively.
Previous data showed no relevant change in the expression of PKC
isoforms under treatment with PEP005 in cancer cells but that
PEP005 may activate PKC and inhibit PKC phosphorylation
(Serova et al, 2008). As expected from our previous results, we
observed that exposure of Colo205 cells to 3mM PEP005 for 20min
increased the phosphorylation of PKCd and activated p38
(Figure 2B). Semiquantitative western blot analysis of expression
of PKC isoforms a, b, d, and e was performed showing that most
cancer cells in our panel expressed various levels of PKC. Attempts
were made to determine whether baseline expressions of those
PKC isoforms correlated with sensitivity to PEP005. In this study,
we further found no statistically significant correlation between
sensitivity to PEP005, and PKC isoforms expression was detectable
neither in our panel of colon cancer cell lines nor in the extended
panel of 10 human cancer cell lines (Figure 2C). The cytotoxicity
profile of PEP005 was compared to that of various chemo-
therapeutic agents including oxaliplatin, cisplatin, doxorubicin,
SN38, 5FU, gemcitabine, vinorelbine, docetaxel, and staurosporine
in our panel of colon cancer cell lines. The IC50 values are reported
in Table 1. In our study, PEP005 displayed a cytotoxicity profile
that differs from that of most cytotoxic agents. Interestingly,
Colo205 cells were more sensitive to PEP005 than to 5FU and
oxaliplatin.
Effects of PEP005 on cell cycle and apoptosis
In Colo205 cells, which were the most PEP005 sensitive cells in our
panel, we further analysed the cell cycle distribution using flow
cytometry. Cells were incubated for 24h with various concentra-
tions of PEP005. Exposure to PEP005 concentrations ranging from
0.03 to 3.0mM led to an inhibition of S-phase entry with an
accumulation of cells in G1 and an increase of the sub-G1 fraction
suggesting apoptosis (Figure 3A). Duration of exposure was shown
to play a role in PEP005-induced effects on the cell cycle, the
maximal inhibition being obtained for 24h exposure (Figure 3B).
In contrast to that observed in Colo205 cells, no change was
observed in HT29 cells that appeared to be more resistant
than Colo205 cells to PEP005. As the increase of the sub-G1
fraction suggested induction of apoptosis, we further confirmed
apoptosis induction using double staining with annexin V-FITC
and PI in cells exposed for 24h to PEP005 at concentrations
ranging 0.03–0.3mM (Figure 3C). In Colo205 cells, we observed a
significant increase of the early apoptosis fraction (annexin V
positive, PI negative) as well as of the late apoptosis fraction
(annexin V positive, PI positive). In contrast, no apoptosis was
detectable in HT29 cells at concentrations ranging from 3 to 30mM
(Figure 3D).
Antiproliferative effects of PEP005-based combinations
Four schedules were used to study the effects of sequential and
simultaneous exposures of PEP005-based combinations. Combina-
tions were made with the cytotoxic agents most frequently used for
Table 1 Antiproliferative effects (IC50 using MTT assay) of PEP005,
staurosporine, and several anticancer agents in a panel of human colon
cancer cell lines
IC50 (lM)
HT29 HCT116 HCC2998 COLO205
PEP005 (1h) 4300 4300 300 35±7
PEP005 (24h) 4100 4300 4300 3±1.4
PEP005 (48h) 140±28 120±24 30±6 0.01±0.002
Staurosporine 0.210±0.01 0.013±0.003 0.080±0.016 0.029±0.001
Cisplatine 25.00±3.33 9.15±0.85 25±5 9.5±2.5
Oxaliplatine 60±12 20±44 ±1.41 8±1.6
Doxorubicin 1.07±0.16 0.10±0.02 0.70±0.14 1.5±0.5
Gemcitabine 0.04±0.008 0.05±0.01 0.04±0.008 20±4
5FU 23.50±0.50 5.25±1.25 10±0.2 240±20
Vinorelbine 0.01±0.002 0.01±0 0.015±0.005 0.02±0.004
Docetaxel 0.001±0.0002 0.4± 0.08 0.0008± 0.0001 0.007±0.001
Cells were treated with PEP005 for 1, 24, or 48h and other drugs for 24h.
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sthe treatment of colorectal cancer: oxaliplatin, SN38 (the active
metabolite of irinotecan) and 5FU as well as several other
anticancer drugs. In schedule 1, PEP005 was added simultaneously
with other drugs for 24h (except for 5FU that was given for
48h). Schedule 2 used a sequential administration of PEP005
for 24h before other drugs. Schedule 3 consisted of the
opposite sequence giving cytotoxics before PEP005. Schedule 4
gave PEP005 first followed by a 24h washout period before
administration of the second drug. Following incubation, effects
were determined using CIs as described previously (Chou and
Talalay, 1984). Results of PEP005-combination studies are
summarised in Table 2.
Antagonistic effects between PEP005 and cisplatin were
observed for all schedules of administration. Concomitant or
sequential exposure to PEP005 and oxaliplatin appeared antag-
onistic in Colo205 cells. However, synergistic effects between the
two drugs were observed when a 24h washout period was included
(schedule 4). Synergism between oxaliplatin and PEP005 was
observed when Colo205 cells were exposed to oxaliplatin 24h and
72h after PEP005 (Figure 4). Combinations of PEP005 with SN38
were also synergistic using sequential exposure. Combinations of
PEP005 with 5FU led to various degrees of additive or synergistic
activity regardless of the sequence of drug exposure except for
concomitant treatment.
We also studied combinations of PEP005 with several other
anticancer agents. Synergistic effects were observed with
doxorubicin for schedules 2 and 3. The sequence of gemcitabine
followed by PEP005 was additive contrasting with the anta-
gonism seen when drugs were administered concomitantly or
when PEP005 was given before gemcitabine. This antagonism
was reversed when gemcitabine was administered 24h after
PEP005 (schedule 4), the combination being synergistic. In
addition, this study showed that sequential exposure to tubulin
inhibitors including vinorelbine and docetaxel with PEP005 were
additive.
Colo205 cells treated with PEP005-based synergistic combina-
tions were analysed using flow cytometry. Cell cycle distribution,
displayed in Figure 5, showed sub-G1 accumulation suggesting
1 h 24 h 48 h
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Figure 2 Antiproliferative effects of PEP005 in cells, according to PKC expression. (A) Cytotoxicity of PEP005 after 1, 24, and 48h exposures in Colo205
cells. (B) Modulation of PKC d and p38 phosphorylation by PEP005 in Colo205 cells. Colo205 cells were treated with PEP005 (0.3mM) for the indicated
time. Protein extracts were then analysed for PKC d and p38 phosphorylation. (C) Correlation between PKC levels and sensitivity to PEP005. Expression
levels of PKC a, b, d, and e were correlated with IC50 of PEP005 in 10 cancer cell lines (K, colon cancer cell lines; J, other cell lines). All values from the
densitometric analysis of western blot are standardised with respect to Colo205. The r
2 value is the correlation coefficient calculated by linear regression
analysis.
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sapoptosis as a result of PEP005 combinations with doxorubicin,
gemcitabine, docetaxel, and vinorelbine. Exposure to oxaliplatin
24h after the end of exposure to PEP005 led to accumulation of
cells in S-phase of cell cycle.
DISCUSSION
Protein kinases C have emerged as novel therapeutic targets for
cancer treatment. A large variety of structurally and mecha-
nistically distinct PKC modulators have been identified and/or
developed as anticancer agents. Protein kinase C modulators such
as bryostatin-1, UCN-01, PKC-412, and PKCa antisense oligo-
nucleotide (aprinocarsen) have been extensively tested in clinical
trials. Although these agents displayed promising results in in vitro
and in vivo experiments, clinical results remained so far
disappointing (Mackay and Twelves, 2007). Only one compound,
aprinocarsen, reached phase III and has failed to demonstrate
benefit in nonsmall-cell lung carcinoma (Paz-Ares et al, 2006).
Researches of novel PKC inhibitors are still ongoing, and new
compounds such as enzastaurin displayed promising preclinical
and clinical activity and are currently being evaluated in phase III
trials (Ma and Rosen, 2007). Discrepancies between preclinical
research and results of clinical trials with PKC modulators pointed
out the need to develop more selective PKC modulators along with
identifying predictive molecular markers that may allow selecting
patients. In addition, several studies have shown that combina-
tions of PKC modulators with conventional cytotoxics may need
preclinical evaluation to determine optimal sequences of admin-
istration before entering clinical trials. Studies with bryostatin-1
have emphasised the importance of the schedule sequence, the
administration of bryostatin-1 before cisplatin, vincristine and
gemcitabine being synergistic, while synergy with paclitaxel
required the administration of bryostatin-1 after paclitaxel
(Koutcher et al, 2000).
Among new compounds, PEP005 appears to be a promising
agent for anticancer treatment. In previously published studies,
PEP005 displayed antiproliferative effects in several human cancer
cell lines (Gillespie et al, 2004; Ogbourne et al, 2004; Hampson
et al, 2005; Cozzi et al, 2006). Studies that evaluated the activity of
PEP005 as a topical agent for human and mouse xenografts have
shown that the predominant mechanism of cell death is necrosis
(Ogbourne et al, 2004) and in some melanoma cell lines apoptosis
was observed (Gillespie et al, 2004). The capacity of PEP005 to
induce apoptosis was further confirmed using leukaemia cancer
cells (Hampson et al, 2005). In addition, PEP005 induced cell
senescence (Cozzi et al, 2006). We have recently tested the
antiproliferative effects of PEP005 in several human cancer cell
lines and we have shown that PEP005 may induce apoptosis in
colon cancer cell lines at clinically relevant concentrations (Serova
et al, 2008). We found that the antiproliferative effects were related
to cell cycle inhibition in the G1 phase as well as the induction
of apoptosis. These effects may be obtained with a wide range
of clinically relevant concentrations. As suggested by our results,
antiproliferative effects may be further optimised by increasing the
duration of exposure to PEP005 to 48h. These data warrant
pursuing PEP005 clinical development in solid tumours.
Comparison of the cytotoxic effects of PEP005 with those of
other anticancer agents confirmed its unique cytotoxic profile,
which is related to its specific mechanism of action. In this study,
we found no correlation between PKC isoforms expression and the
antiproliferative effects of PEP005. We previously showed that
PEP005 induced activation of PKCd and reduced expression of
PKCa resulting in apoptosis mediated by activation of Ras/Raf/
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Figure 3 Cell cycle effects and apoptosis induction by PEP005 in colon cancer cells. Effects of increasing concentrations of PEP005 for 24h (A) on cell
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(Serova et al, 2008). In contrast, in the HT29 resistant cell line, no
activation of PKCd, MAPK, or AKT was detectable. Further studies
may identify molecular markers to help predict sensitivity and/or
resistance to PEP005 in human solid tumours.
Considering that concentrations required to observe cytotoxic
effects, apoptosis, and/or cell cycle blockage may be limited by
toxicity when PEP005 is given to patients with solid tumours, we
considered that it is essential to evaluate combinations which
could allow the use of lower concentrations of PEP005 and which
might improve the cytotoxic effects of already used anticancer
agents. In this study, we showed that PEP005 has additive and/or
synergistic effects when combined with a large variety of classical
cytotoxic drugs such as oxaliplatin, cisplatin, doxorubicin, SN38,
5FU, gemcitabine, vinorelbine, and docetaxel. However, strong
evidences of schedule dependency were observed. For example,
concomitant administrations of PEP005 and several cytotoxics
were mainly antagonistic, suggesting that the cell cycle arrest
induced by PEP005 may prevent the cytotoxicity of drugs that
target DNA and microtubules. Interestingly, considering that cell
cycle blockage induced by PEP005 in late G1 may last for up to
24h, we further considered experiments introducing a 24h lag
time between PEP005 and subsequent exposure to cytotoxics. This
finding was observed with oxaliplatin, a major drug used for the
treatment of colon cancer. Known mechanisms of action of
oxaliplatin may partly explain our findings. For instance,
oxaliplatin cytotoxicity is known to be related to platinum-DNA
adduct formation resulting in cell cycle blockage in the G2/M
phase of cell cycle. Cell cycle arrest by PEP005 in phase G1 may
result in decreasing the window of opportunity for incorporation
of platinum into DNA and also increasing duration of DNA repair
during G1. Further studies looking at platinum-DNA adducts
formation may further provide insight on mechanisms resulting
into antagonistic effects. However, introducing a 24h lag time
between PEP005 and oxaliplatin may allow cells to re-enter cell
cycle, thus providing more opportunity for platinum-DNA adduct
formation and reducing the duration during which repair of
platinum-DNA adducts occur, thereby increasing the cytotoxicity
of the combination. In contrast, PEP005 combinations with 5FU
were shown to be synergistic, regardless of schedules, which might
be, at least in part, explained by known effects of 5FU on cell cycle
that does depend on duration of the G0/G1 phase of cell cycle.
While further in vivo studies are warranted to confirm the
effectiveness of PEP005 combinations with cytotoxic agents, our
finding may help designing trials in which a lag time between
PEP005 and cytotoxic may be introduced to optimise cytotoxic
activity.
In summary, modulation of PKC by simultaneous activation of
PKCd and inhibition of PKCa using PEP005, displayed antiproli-
ferative effects due to late G1 cell cycle arrest and/or apoptosis
induction at concentrations that may be reached in clinical trials.
These effects appear time dependent and are likely to require
prolonged exposure to PEP005. Combinations with other cytotoxic
Table 2 Mean combination index values for PEP005-based combina-
tions in Colo205 colon cancer cells
Combinations with Combination index mean (CI 95%)
Cisplatin
A 1.52 (1.03–2.02)
B 8.85 (2.79–14.91)
C 24.91 ( 8.96 to 58.79)
D 1.49 (0.23–2.74)
Oxaliplatin
A 18.67 (6.58–30.76)
B 1.95 (0.85–3.0)
C 1.81 (1.41–2.21)
D 0.28 (0.17–0.4)
SN38
B 0.53 (0.10–0.97)
C 0.70 (0.48–0.92)
5FU
A 1.49 (1.19–1.80)
B 0.71 (0.31–0.80)
C 1.09 (0.52–1.66)
D 0.56 (0.31–0.81)
Doxorubicin
A 1.04 (0.73–1.36)
B 0.74 (0.46–1.02)
C 0.92 (0.46–1.38)
D 1.13 (0.8–1.46)
Gemcitabine
A 1.77 (1.32–2.22)
B 7.29 (0.58–14.01)
C 1.17 (0.83–1.51)
D 0.68 (0.47–0.89)
Vinorelbine
A 18.67 (6.58–30.76)
B 1.95 (0.84–3.06)
C 0.52 (0.09–0.95)
D 1.233 (0.80–1.66)
Docetaxel
A 6.12 (2.53–9.71)
B 1.17 (0.73–1.61)
C 1.16 (0.80–1.51)
D 1.09 (0.73–1.44)
CI: confidence interval. A: 24h PEP005+drug. B: 24h PEP005 then 24h drug. C: 24h
drug then 24h PEP005. D: 24h PEP005 then 24h washout then 24h drug.
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Figure 4 PEP005–oxaliplatin combinations in Colo205 colon cancer
cells. The following four schedules were investigated using the Chou and
Talalay method: (A) Exposure of PEP005 for 24h along with oxaliplatin;
(B) PEP005 exposure for 24h followed by 24h exposure to oxaliplatin;
(C) 24h exposure to oxaliplatin followed by 24h exposure to PEP005; and
(D) 24h exposure to PEP005 followed by a 24h washout period then
followed by exposure to oxaliplatin for 24h.
Antiproliferative effects of PEP005 in colon cancer cells
KA Benhadji et al
1813
British Journal of Cancer (2008) 99(11), 1808–1815 & 2008 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sdrugs may require giving administration of PEP005 before cytotoxics
with a lag time of 24h. Thus far, no target marker has been identified
that may predict PEP005 activity in colon cancer cell lines, thus
warranting further preclinical research aimed toward detecting
molecular surrogate markers of sensitivity to PEP005.
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concentrations, washed, and analysed by flow cytometry at 24h post-incubation in drug-free medium.
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